Peptide-Based Gastrointestinal Disorders Therapeutics Market By Drug Type (Gastrointestinal Peptides, Ghrelin-Based Therapies, Secretin-Based Therapies), By Application (Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), Gastroesophageal Reflux Disease (GERD)), By End-User (Hospitals & Clinics, Gastroenterology Centers, Research Institutions), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptide-Based Gastrointestinal Disorders Therapeutics Market was valued at USD 1.9 billion in 2024-e and will surpass USD 3.1 billion by 2030; growing at a CAGR of 8.5% during 2025 - 2030.

The peptide-based gastrointestinal disorders therapeutics market is witnessing substantial growth, driven by advancements in peptide therapies and the increasing prevalence of gastrointestinal diseases. Peptide-based drugs have shown significant potential in treating a variety of gastrointestinal disorders due to their ability to target specific receptors and pathways in the digestive system. These therapies offer promising alternatives to conventional treatments, especially for conditions such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Gastroesophageal Reflux Disease (GERD).

With the growing incidence of gastrointestinal disorders globally, there is a rising demand for effective and targeted therapies. Peptide-based drugs, particularly those targeting gastrointestinal peptides, ghrelin, and secretin, have garnered attention for their therapeutic efficacy. As research into gastrointestinal peptides advances, the market is expected to see continued growth, supported by innovation in drug formulations and the increasing acceptance of peptide-based therapeutics for treating complex gastrointestinal conditions.

Gastrointestinal Peptides Segment Leads Due to Wide Applications in Various Disorders

The gastrointestinal peptides segment is the largest in the peptide-based gastrointestinal disorders therapeutics market, owing to their broad application in treating various gastrointestinal disorders. These peptides, which include a range of biologically active molecules, have been shown to effectively modulate the gastrointestinal system. By targeting specific receptors and regulating digestive processes, gastrointestinal peptides help in treating disorders such as IBS, IBD, and GERD.

The use of gastrointestinal peptides is especially significant for managing conditions involving the gut-brain axis, where these peptides influence gastrointestinal motility, inflammation, and secretion. As a result, gastrointestinal peptides have become a key focus of therapeutic development in the treatment of functional and inflammatory gastrointestinal disorders. Their wide-ranging benefits in managing complex gastrointestinal conditions have positioned them as a dominant therapeutic class in the market.

Inflammatory Bowel Disease (IBD) is the Fastest Growing Application Owing to Rising Prevalence

The inflammatory bowel disease (IBD) application segment is the fastest growing in the peptide-based gastrointestinal therapeutics market, primarily driven by the rising prevalence of IBD globally. IBD, which includes Crohn’s disease and ulcerative colitis, is a chronic condition characterized by inflammation of the digestive tract. The increasing incidence of IBD, coupled with the limitations of traditional therapies, has led to a growing interest in peptide-based treatments.

Peptide therapies, particularly those targeting specific inflammatory pathways, are gaining traction for their ability to provide more precise and effective treatment options for IBD patients. These therapies help in modulating immune responses and reducing inflammation in the gastrointestinal tract, offering potential alternatives to corticosteroids and immunosuppressive drugs. The effectiveness of peptide-based treatments in IBD is expected to drive continued market growth in this application.

Hospitals & Clinics Segment is Largest End-User Due to Direct Patient Care

The hospitals and clinics segment is the largest end-user in the peptide-based gastrointestinal therapeutics market, owing to their central role in treating patients with gastrointestinal disorders. Hospitals and clinics are the primary healthcare settings where patients suffering from conditions like IBS, IBD, and GERD are diagnosed and treated. The infrastructure available in these settings, along with the expertise of healthcare providers, makes them the ideal locations for administering peptide-based therapies.

Moreover, hospitals and clinics offer specialized care, particularly for patients with severe or complex gastrointestinal disorders, which require precise treatment regimens. The increasing use of peptide-based therapies in these settings is expected to continue driving the market's growth as more patients seek advanced treatments for chronic gastrointestinal conditions.

North America Dominates the Market Due to Advanced Healthcare Infrastructure

North America is the dominant region in the peptide-based gastrointestinal disorders therapeutics market, owing to its advanced healthcare infrastructure, high healthcare expenditure, and a large patient population suffering from gastrointestinal diseases. The region also benefits from a strong pharmaceutical industry and significant investments in research and development, which have accelerated the adoption of peptide-based therapies.

The United States, in particular, has a high prevalence of gastrointestinal disorders, including IBS, IBD, and GERD, driving demand for effective treatments. The presence of leading pharmaceutical companies and research institutions in North America has facilitated the development and commercialization of peptide-based gastrointestinal therapeutics, making the region the largest market for these therapies.

Competitive Landscape

The peptide-based gastrointestinal disorders therapeutics market is competitive, with several pharmaceutical and biotechnology companies focusing on the development of peptide-based drugs for gastrointestinal conditions. Key players are engaged in extensive research to improve the efficacy, stability, and bioavailability of gastrointestinal peptides, ghrelin-based therapies, and secretin-based therapies. Companies are also exploring combination therapies to enhance treatment outcomes for patients with complex gastrointestinal disorders.

In addition to large pharmaceutical firms, smaller biotechnology companies are making significant strides in peptide drug development, particularly in the areas of IBS, IBD, and GERD. The competitive landscape is driven by factors such as the ability to bring innovative therapies to market, the pricing strategies of companies, and the regulatory approval process. With ongoing advancements in peptide-based drug development, the competitive dynamics of the peptide-based gastrointestinal therapeutics market are expected to evolve, offering new opportunities for both established and emerging players in the field..

List of Leading Companies:

• Takeda Pharmaceutical Company
• Novartis
• Pfizer
• Eli Lilly and Company
• Merck & Co.
• GlaxoSmithKline
• Johnson & Johnson
• Amgen Inc.
• AstraZeneca
• Sanofi
• Bristol-Myers Squibb
• Abbott Laboratories
• Boehringer Ingelheim
• Gilead Sciences
• Astellas Pharma

Recent Developments:

• In December 2024, Takeda Pharmaceutical Company launched a new ghrelin-based therapy for IBS treatment.
• In November 2024, Novartis received FDA approval for a new peptide-based treatment for GERD.
• In October 2024, Pfizer introduced a new secretin-based peptide drug for inflammatory bowel disease.
• In September 2024, Merck & Co. expanded its peptide-based gastrointestinal drug portfolio for treating digestive disorders.
• In August 2024, Amgen Inc. announced a partnership with a biotech firm to develop peptide therapies for gastrointestinal diseases

Report Scope: